Clinical trials: Affective Disorder
Traumatic Brain Injury
Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.
Growth Hormone (GH) deficiency, defined by insufficient GH response to a variety of stimulating compounds, is found in 20-35% of adults who suffer traumatic brain injuries (TBI) requiring inpatient rehabilitation1.
- Trial name
- Growth-TBI (NCT00766038)
- Testing
- Recombinant human Growth Hormone
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
- Trial name
- NCT01371721
- Testing
- DVS SR
- Where
- 35 sites in United States, Mexico
- Volunteers
- 269 people
- Sponsor
- Pfizer
Depression
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.
- Trial name
- NCT00456014
- Testing
- Escitalopram, Desipramine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder, Depression, Bipolar
Adjunctive Ziprasidone in the Treatment of Bipolar I Depression
The purpose of this study is to determine if a treatment regimen of ziprasidone plus a mood stabilizer is safe and effective in the short term treatment of Bipolar I Depression.
- Trial name
- NCT00483548
- Testing
- Ziprasidone
- Where
- 70 sites in United States, Australia and 1 more
- Volunteers
- 298 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Brain Imaging Techniques That Predict Antidepressant Responsiveness
Do functional brain changes occur during Venlafaxine ER (extended release) versus Fluoxetine treatment and do changes in selective structures, such as the amygdala, predict treatment response?
- Trial name
- WyethKolden (NCT00909155)
- Testing
- Venlafaxine ERT, Fluoxetine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Schizophrenia, Bipolar Disorder
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
The purpose of this study is to assess the efficacy of d-cycloserine (DCS) as an augmentation strategy in two psychotic patients with a triplication (4 copies) of the glycine decarboxylase (GLDC) gene.
- Trial name
- DCS (NCT02304432)
- Testing
- D-cycloserine
- Volunteers
- 2 people
- Sponsor
- Mclean Hospital
Bipolar Depression
Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression
There have been reports that stimulants may be effective for bipolar depression without triggering mania. This study will examine whether lisdexamfetamine can improve depressive symptoms over the course of eight weeks.
- Trial name
- NCT01051440
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Depressive Symptoms, Depression
Self-guided Treatment for Adolescents Navigating Depression
The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression.
- Conditions
- Depressive Symptoms, Depression, Depressive Disorder, Depressive Episode
- Trial name
- NCT05462652
- Testing
- Active Intervention
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Limbix Health, Inc.
Major Depressive Disorder
Escitalopram in Adult Patients With Major Depressive Disorder
This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression.
- Trial name
- NCT00668525
- Testing
- Escitalopram
- Where
- 45 sites in United States
- Volunteers
- 877 people
- Sponsor
- Forest Laboratories
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
Self-Injurious Behavior, Self Harm
Treating Self Injurious Behavior: A Novel Brain Stimulation Approach
The purpose of this study is to explore the tolerability and effectiveness of transcranial direct current stimulation (tDCS) as a potential treatment for non-suicidal self-injury (NSSI).
- Conditions
- Self-Injurious Behavior, Self Harm, Self-injury, Self-inflicted Injury
- Trial name
- NCT04244786
- Testing
- Transcranial direct current stimulation, No intervention
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Major
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.
- Trial name
- NCT01564862
- Testing
- vortioxetine (Lu AA21004), Duloxetine
- Where
- 92 sites in United States, Bulgaria and 5 more
- Volunteers
- 602 people
- Sponsor
- Takeda
Depression, Bipolar, Bipolar Disorder
Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Bipolar disorder is a severe and disabling disorder. The course of illness is often progressive but is highly heterogeneous between individuals and within the lifetime for an individual.
- Conditions
- Depression, Bipolar, Bipolar Disorder, Mood Disorders, Mental Disorder
- Trial name
- NCT05436613
- Testing
- Transcranial Direct Current Stimulation
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- University of East London
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Psychosis
Effectiveness of Cognitive Remediation in a Supported Education Setting
The purpose of this study is to determine whether cognitive remediation as an adjunct to supported education, will result in improved cognitive functioning, symptoms, and performance in academic domains for persons with psychosis…
- Trial name
- NCT01492439
- Testing
- Cognitive Remediation, Supported Education
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in Japanese adult participants with Major Depressive Disorder (MDD).
- Trial name
- NCT01808612
- Testing
- Fluoxetine
- Where
- 16 sites in Japan
- Volunteers
- 513 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder
Study Of 323U66 SR In Major Depressive Disorder
This study was designed to evaluate the efficacy and safety in major depressive disorder patients.
- Trial name
- NCT00135512
- Testing
- bupropion hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 234 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.